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Protease-activated receptor-1 (PAR1) is a G-protein-coupled receptor
(GPCR) for the coagulant protease thrombin. Similar to other GPCRs,
PAR1 is promiscuous and couples to multiple heterotrimeric G-protein
subtypes in the same cell and promotes diverse cellular responses.
The molecular mechanism by which activation of a given GPCR with
the same ligand permits coupling to multiple G-protein subtypes
is unclear. Here, we report that N-linked glycosylation of PAR1 at
extracellular loop 2 (ECL2) controls G12/13 versus Gq coupling specific-
ity in response to thrombin stimulation. A PAR1 mutant deficient in
glycosylation at ECL2 was more effective at stimulating Gq-mediated
phosphoinositide signaling compared with glycosylated wildtype
receptor. In contrast, wildtype PAR1 displayed a greater efficacy at
G12/13-dependent RhoA activation compared with mutant receptor
lacking glycosylation at ECL2. Endogenous PAR1 rendered deficient
in glycosylation using tunicamycin, a glycoprotein synthesis inhibitor,
also exhibited increased PI signaling and diminished RhoA activation
opposite to native receptor. Remarkably, PAR1 wildtype and glyco-
sylation-deficient mutant were equally effective at coupling to Gi and
β-arrestin-1. Consistent with preferential G12/13 coupling, thrombin-
stimulated PAR1 wildtype strongly induced RhoA-mediated stress
fiber formation compared with mutant receptor. In striking contrast,
glycosylation-deficient PAR1 was more effective at increasing cellular
proliferation, associated with Gq signaling, than wildtype receptor.
These studies suggest that N-linked glycosylation at ECL2 contributes
to the stabilization of an active PAR1 state that preferentially couples
to G12/13 versus Gq and defines a previously unidentified function for
N-linked glycosylation of GPCRs in regulating G-protein signaling bias.
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Protease-activated receptor-1 (PAR1) is the prototypical mem-ber of a family of four G-protein-coupled receptors (GPCRs)
that are activated by specific proteases including the coagulant
protease thrombin. Thrombin is generated during vascular injury and
inflammation and promotes hemostasis, thrombosis, and inflamma-
tory and proliferative responses (1). PAR1 is crucial for thrombin-
elicited responses in cell types such as human platelets, fibroblasts,
and endothelial cells and accordingly is an important drug target for
vascular and thrombotic diseases (2). PAR1 has also been implicated
in progression of certain malignant cancers (3).
Thrombin activates PAR1 through proteolytic cleavage of the
extracellular N terminus, which unmasks a new N-terminal domain
that acts as a tethered ligand that binds intramolecularly to the
receptor to induce transmembrane signaling (4, 5). A synthetic
peptide that mimics the first six residues of the newly formed N
terminus, SFLLRN, can activate PAR1 independent of thrombin
and receptor cleavage. Several studies indicate that residues within
the tethered ligand sequence interact specifically with residues in the
extracellular loop 2 (ECL2) of PAR1 to facilitate receptor activation
(6, 7). The high-resolution crystal structure of PAR1 bound to the
antagonist vorapaxar also reveals a superficial hydrophobic binding
pocket close to the extracellular surface (8). These studies suggest
that the PAR1 tethered ligand likely binds superficially to ECL2 to
induce conformational changes sufficient for receptor activation.
Once activated by thrombin, PAR1 couples to multiple hetero-
trimeric G-protein subtypes concomitantly in the same cell. PAR1
stimulates phospholipase C-catalyzed hydrolysis of phosphoinosi-
tides (PI) through Gq and inhibits adenylyl cyclase through Gi at the
same time (9). Concurrently, PAR1 couples to G12/13, leading to
activation of Rho guanine nucleotide exchange factors and RhoA
signaling (10). Similar to other GPCRs, the intracellular loop 2
(ICL2) and putative eighth helix have been implicated in PAR1
interaction with G proteins (11, 12). In addition, particular residues
within ICL2 appear to dictate PAR1–G-protein subtype coupling
specificity (13). However, it remains unclear how the tethered ligand
of PAR1 generated by thrombin cleavage might interact differently
with the receptor to specify unique coupling to distinct G-protein
subtypes in the same cell.
GPCRs are dynamic molecules that assume different confor-
mational states. Consequently, different ligands can stabilize unique
active conformations of the same GPCR and facilitate activation of
distinct signaling effectors such as G proteins or β-arrestins (14, 15).
This process is termed biased agonism or functional selectivity.
Quantification of GPCR signaling bias has also been shown to
describe the effects of receptor mutation on the relative interactions
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with signaling effectors (16, 17). Besides binding of ligands to allo-
steric sites on the receptor, GPCR interaction with other proteins
and segregation into plasma membrane microdomains have been
reported to affect receptor bias toward particular effectors. How-
ever, whether posttranslational modification of a given GPCR af-
fects ligand-induced coupling to distinct signaling effectors is not
known. Here, we report that asparagine (N)-linked glycosylation of
PAR1 at ECL2 regulates G12/13- versus Gq-protein coupling speci-
ficity, which modulates the robustness of thrombin-induced G12/13-
dependent RhoA mediated stress fiber formation and cellular
proliferation associated with Gq signaling in fibroblasts. These find-
ings are the first, to our knowledge, to define a function for N-linked
glycosylation of a GPCR in regulating G-protein signaling bias.
Results
PAR1 Deficient in Glycosylation at ECL2 Exhibits Enhanced Gq-Mediated
PI Signaling.PAR1 containing amino acid Asn250Ala and Asn259Ala
mutations that lacks N-linked glycosylation at ECL2, designated NA
ECL2, displayed a greater capacity to stimulate PI hydrolysis com-
pared with wildtype (WT) receptor following exposure to thrombin
in HeLa cells (18). Similar differences in thrombin-induced PI hy-
drolysis were observed in COS-7 cells transiently expressing com-
parable levels of cell surface PAR1 WT and NA ECL2 mutant (Fig.
S1 A and B). To determine whether activated PAR1 coupling to Gq
protein specifically mediates enhanced PI signaling, siRNA was
used to deplete cells of Gαq expression (Fig. 1A). HeLa cells stably
expressing PAR1WT and NA ECL2 mutant were transfected with
nonspecific or Gαq-specific siRNAs and labeled with myo-
[3H]inositol. Thrombin stimulated a greater increase in PI hydrolysis
in PAR1 NA ECL2 cells compared with WT cells transfected with
nonspecific siRNA that was not due to differences in receptor ex-
pression (Fig. 1 A and B). However, both PAR1 WT and NA ECL2
cells deficient in Gαq expression failed to elicit a thrombin response
(Fig. 1A), indicating that activated PAR1-induced PI hydrolysis is
mediated by Gq in HeLa cells.
To determine if glycosylation of PAR1 at ECL2 affects
Gq-stimulated PI signaling by modulating receptor association
with Gαq protein, we performed coimmunoprecipitation (co-IP)
assays. HeLa cells stably expressing PAR1 WT or NA ECL2
mutant were transiently transfected with different amounts of
Fig. 1. PAR1 NA ECL2 mutant exhibits enhanced Gαq-mediated PI hydrolysis. (A) FLAG–PAR1 WT or FLAG–NA ECL2 mutant HeLa cells transfected with
nonspecific (ns) or Gαq siRNA labeled with myo-[3H]inositol were stimulated with 10 nM α-Th. Data (mean ± SD; n = 3) are from three independent ex-
periments and were significant (***P < 0.001). (B) PAR1 surface expression (mean ± SD; n = 3) was determined by ELISA. Control (Ctrl) is secondary antibody
only. (Inset) Immunoblots of cell lysates. (C) FLAG–PAR1 WT or FLAG–NA ECL2 mutant HeLa cells transiently transfected with HA–Gαq were lysed, immu-
noprecipitated, and immunoblotted as indicated. Data (mean ± SD; n = 3) are from three independent experiments and were significant (**P < 0.01).
(D) FLAG–PAR1 WT or FLAG–NA ECL2 mutant HeLa cells transfected with HA–Gαq or untransfected (UT) cells were treated with 10 nM α-Th, lysed, immuno-
precipitated, and immunoblotted as indicated. Data (mean ± SEM; n = 4) are from four independent experiments and were significant (*P < 0.01).















Gαq plasmid. PAR1 was immunoprecipitated, and coassociated
Gαq was detected by immunoblotting. PAR1 NA ECL2 exhibited
a greater capacity to co-IP with Gαq basally compared with WT
receptor or IgG control (Fig. 1C, lanes 1, 4, and 7). Remarkably,
thrombin induced a twofold increase in PAR1 WT–Gαq associa-
tion compared with control cells (Fig. 1D, lanes 1–3). Although
PAR1 NA ECL2 mutant exhibited a statistically greater capacity
to interact with Gαq basally (Fig. 1 C and D), receptor–Gαq
coassociation was not further increased by thrombin stimulation
(Fig. 1D, lanes 4 and 5). The PAR1 NA ECL2 mutant expressed
in COS-7 cells also showed enhanced association with Gαq protein
compared with WT receptor (Fig. S1C), indicating that the ob-
served findings are not cell type specific.
In many cell types, PAR1 and Gq localize to caveolae (19,
20), plasma membrane lipid rafts enriched in cholesterol and
caveolin-1. To exclude the possibility that altered PAR1 WT
versus NA ECL2 mutant activation of Gq protein might be due
to differential localization in caveolae, sucrose gradient frac-
tionation was used. A similar distribution of PAR1 WT, NA
ECL2, and Gq proteins in caveolin-1 enriched and nonenriched
fractions was observed (Fig. S1D). These data suggest that
thrombin-activated PAR1 lacking glycosylation at ECL2 dis-
plays an enhanced capacity to couple to Gq-dependent PI sig-
naling in different cell types that is not due to alterations in
receptor expression or distribution to caveolae.
PAR1 NA ECL2 Displays Diminished G12/13-Mediated RhoA Signaling.
To examine whether glycosylation at ECL2 regulates PAR1 cou-
pling to other G-protein subtypes, we examined RhoA activation,
an effector of G12/13 proteins. HeLa cells stably expressing com-
parable PAR1 WT and NA ECL2 at the cell surface were stim-
ulated with thrombin, and activation of RhoA was measured using
GST-rhotekin Rho-binding domain (RBD) pull-down assays (21).
Thrombin induced a robust increase in RhoA activation at 2.5 min
in PAR1WT cells that subsided after 15–30 min (Fig. 2A, lanes 3–
6), whereas untransfected cells not expressing PAR1 were not
responsive (Fig. 2A, lanes 1 and 2). In contrast, RhoA activation
was significantly reduced in thrombin-treated PAR1 NA ECL2
cells examined over the same time frame (Fig. 2A, lanes 3–10).
Consistent with these findings, activated PAR1 WT was more
potent at stimulating RhoA activation than the NA ECL2 mutant
assessed at earlier time points (Fig. S2A). The peptide agonist
SFLLRN also significantly increased RhoA activation in PAR1 WT
cells compared with NA ECL2 expressing cells (Fig. 2B, lanes 4–9),
indicating that neither thrombin binding nor proteolytic cleavage
contribute to differential RhoA activation. Compared with PAR1
NA ECL2 mutant, RhoA activation induced by thrombin-activated
PAR1 WT was also markedly increased in COS-7 cells (Fig. S2B).
These data suggest that activated PAR1 WT has a greater capacity
to induce RhoA signaling compared to mutant receptor deficient in
glycosylation at ECL2.
To determine if the differences in RhoA activation exhibited
by PAR1 WT versus NA ECL2 mutant are mediated by G12/13
proteins, siRNAs were used to deplete cells of Gα12 and/or Gα13
expression. PAR1 WT and NA ECL2 mutant-expressing HeLa cells
were transfected with nonspecific, Gα12, Gα13, or Gα12 and Gα13
siRNAs and then stimulated with thrombin. Immunoblotting anal-
ysis indicates that siRNAs specifically depleted Gα12 or Gα13 protein
in PAR1 WT and NA ECL2 cells (Fig. 3 A and B). Thrombin-
activated PAR1WT caused a significant increase in RhoA activation
in nonspecific siRNA control cells that was virtually abolished in cells
depleted of either Gα12 or Gα13 proteins (Fig. 3A, lanes 5–8). The
modest increase in RhoA activation observed in thrombin treated
PAR1 NA ECL2 siRNA transfected control cells was also
significantly inhibited in Gα12 and Gα13 knockdown cells (Fig.
3B, lanes 5–8). These findings indicate that PAR1-induced
RhoA activation is dependent on G12/13 proteins.
We next examined if PAR1 WT and NA ECL2 mutant
showed differences in G12/13 association using co-IP. HeLa cells
stably expressing PAR1 WT and NA ECL2 mutant were tran-
siently transfected with increasing amounts of Gα12 plasmid.
Cells were then stimulated with thrombin and immunopreci-
pitated, and the presence of coassociated Gα12 protein was
detected. PAR1 WT showed greater association with Gα12
compared with NA ECL2 mutant basally when expressed at low
levels (Fig. 4A, lanes 1–5 and 7–9) and after thrombin stimulation
(Fig. 4A, lanes 6 and 10). PAR1 WT also exhibited a preference
for Gα13 association compared with the NA ECL2 mutant both
in the presence and absence of thrombin stimulation (Fig. S3).
Bioluminescence resonance energy transfer (BRET) measurement
Fig. 2. PAR1 WT and NA ECL2 differentially activate RhoA. FLAG–PAR1 WT and NA ECL2 mutant HeLa cells displaying similar cell surface expression (WT,
0.363 ± 0.079; NA ECL2, 0.363 ± 0.049, OD units) were treated with 10 nM α-Th (A) or 100 μM SFLLRN (B), lysed, and processed for GST-RBD pull-down assays,
and activated RhoA was detected by immunoblotting. UT cells were processed similarly. The data (mean ± SD; n = 3) were normalized to total RhoA, are
representative of three independent experiments, and were significant (*P < 0.05; ***P < 0.001). NS, not significant.
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was also used to assess PAR1–Gα12 association in living cells.
COS-7 cells were transiently transfected with either full-length
PAR1 WT or NA ECL2 mutant fused to YFP at the C terminus
and Gα12–Rluc that yielded optimal expression (Fig. S4). Cells
were then either left untreated or treated with thrombin, and the
net BRET signal was quantified. Thrombin induced a statistically
significant increase in the net BRET response elicited by PAR1
WT–YFP and Gα12–Rluc compared with untreated control cells
(Fig. 4B), suggesting that the activated PAR1 WT–Gα12 complex
undergoes a conformational change. In contrast, thrombin failed
to induce a change in BRET signal in cells coexpressing PAR1 NA
ECL2 and Gα12–Rluc (Fig. 4B). These studies suggest that activa-
tion of PAR1 glycosylated at ECL2 results in a conformational state
that preferentially couples to G12/13.
Glycosylation of PAR1 at ECL2 Does Not Affect Gi Coupling or β-arrestin-1
Recruitment. In addition to Gq and G12/13, PAR1 is known to
signal through the Gi protein in various cell types (1, 9). To
investigate whether glycosylation of PAR1 at ECL2 regulates
coupling to Gi, we examined PAR1–Gi association by BRET.
COS-7 cells were transiently transfected with a constant
amount of Gαi–Rluc and increasing amounts of either PAR1
WT–YFP or NA ECL2–YFP, and the net BRET was deter-
mined. A hyperbolic increase in net BRET was observed as the
ratio of PAR1 WT–YFP to Gαi–Rluc expression was increased
(Fig. 5A), suggesting a specific interaction. PAR1 NA ECL2–
YFP and Gαi–Rluc saturation curves also yielded a hyperbolic
increase in the net BRET signal (Fig. 5A), suggesting that
glycosylation of PAR1 at ECL2 does not affect basal associ-
ation with Gi protein. We next examined whether thrombin
induced a change in PAR1–Gi association. In COS-7 cells
coexpressing equivalent amounts of either PAR1 WT–YFP or
NA ECL2–YFP together with Gαi–Rluc (Fig. S5 A and B), the
addition of thrombin resulted in a rapid and transient increase
in net BRET that peaked at 1 min and returned to baseline
(Fig. 5B). These findings indicate that activated PAR1 coupling
to Gi is not affected by glycosylation at ECL2. These results
were confirmed by examining PAR1–Gαi association using co-
IP. Activation of either PAR1 WT–YFP or NA ECL2–YFP
with thrombin resulted in a marked fourfold increase in Gαi–
Rluc association compared with untreated control cells (Fig. 5C),
consistent with the equal capacity of both PAR1 WT and NA
ECL2 to associate with Gi protein.
In addition to G proteins, many GPCRs display bias toward
the multifunctional β-arrestin adaptor proteins (22). Since the
β-arrestin-1 isoform is the principal regulator of thrombin-acti-
vated PAR1 signaling (23, 24), recruitment of β-arrestin-1 to
PAR1 was examined by BRET. Intriguingly, PAR1 WT and NA
ECL2 expressed at similar levels were equally effective at recruiting
β-arrestin-1 following thrombin stimulation (Fig. 5 D and E and
Fig. S5C), indicating that glycosylation does not affect receptor–
β-arrestin-1 association. Together, these data suggest that unlike
G12/13 and Gq, PAR1 deficient in glycosylation at ECL2 displays no
bias toward Gi or β-arrestin-1.
Quantifying PAR1 signaling bias. The operational model of agonism
was next used to quantify the G-protein coupling bias of PAR1
WT versus NA ECL2 mutant (25, 26). The concentration–
response curves of Gq-stimulated PI hydrolysis, G12/13-induced
RhoA activation, and Gi-activated PAR1 association (BRET)
(Fig. S6) were normalized to receptor expression and fitted to
the Black–Leff model of agonism to obtain the dissociation
constant of the agonist–receptor complex (KA) and an estima-
tion of the τ transducer constant. The parameters τ and KA
provide an approximation of the signal transduction efficiency
and intrinsic agonist efficacy (Tables S1 and S2). The trans-
duction coefficient for each pathway was then calculated as log
(τ/KA). To determine the relative bias of PAR1 NA ECL2
mutant to WT receptor, Gi BRET response was used as the
reference pathway, because Gi displayed the least difference
between WT and NA ECL2 mutant receptor. Each of the
PAR1 WT and NA ECL2 mutant G-protein signaling assays
were performed in the same cell type with comparable cell
surface expression (Fig. S6). To compare thrombin-induced Gq
and G12/13 signaling pathway bias between the PAR1 WT and NA
ECL2 mutant, the ΔΔlog(τ/KA) was calculated (Table 1 and Fig.
S6). The calculated biases [ΔΔlog(τ/KA) values] indicate that
PAR1 NA ECL2 mutant is 0.58-fold less effective at coupling to
the G12/13–RhoA pathway compared with WT receptor, whereas
PAR1 NA ECL2 is 5.27-fold more effective at stimulating
Gq-induced PI hydrolysis than WT receptor. These findings
strongly suggest that N-linked glycosylation of PAR1 at ECL2
regulates G12/13-versus Gq-protein bias signaling.
Fig. 3. Thrombin-induced RhoA activation requires Gα12 and Gα13 expression. FLAG–PAR1WT (A) or NA ECL2 mutant (B) HeLa cells transfected with siRNAs were
treated with 10 nM α-Th and processed for GST-RBD pull-down assays, and RhoA activation was determined. Cell lysates were immunoblotted as indicated. Data
(mean ± SD; n = 3) are from three independent experiments and were significant (***P < 0.001).















Glycosylation-deficient endogenous PAR1 displays G-protein signaling
bias. PAR1 is expressed in endothelial cells and signals through
Gq and G12/13 to promote inflammatory responses (27). To de-
termine if glycosylation of endogenous PAR1 regulates G-protein
signaling bias in human cultured endothelial cells, we used the
pharmacological inhibitor tunicamycin, which blocks the first step in
glycoprotein synthesis. Glycosylated PAR1 migrates as a broad
∼75-kDa protein that was reduced to its predicted molecular
weight of ∼40 kDa following treatment with tunicamycin
(Fig. 6A, lanes 3 and 5), consistent with previous studies (18).
Tunicamycin also caused partial loss of PAR1 surface expression
(Fig. S7A); however, the majority of the receptor trafficked to
the cell surface. This was confirmed by examining PAR1’s
susceptibility to cleavage by thrombin at 4 °C (18), which
caused a shift in the size of the major PAR1 species in both
control and tunicamycin-treated cells (Fig. 6A, lanes 3–6). In
tunicamycin-treated endothelial cells expressing deglycosylated
endogenous PAR1, thrombin induced a significantly greater in-
crease in PI hydrolysis compared with control cells expressing the
glycosylated native receptor (Fig. 6B). In striking contrast,
thrombin caused a marked response in RhoA activation under
control conditions that was virtually ablated in cells treated with
tunicamycin (Fig. 6C). To ensure that tunicamycin does not
globally affect cell signaling, epidermal growth factor (EGF)-
induced ERK1/2 activation was examined and shown to be equiv-
ocal in control and tunicamycin-treated cells (Fig. S7B). These
findings provide evidence that N-linked glycosylation of PAR1 at
ECL2 promotes enhanced G-protein-mediated PI signaling and
diminished RhoA activation in a natural context.
PAR1 NA ECL2 Exhibits Reduced RhoA-Mediated Stress Fiber Formation
and Enhanced Cellular Proliferation. To test whether the effects of
N-linked glycosylation on PAR1 differential coupling to Gq versus
G12/13 impacts cellular responses, we examined actin stress fiber
formation. Serum-deprived HeLa cells expressing PAR1 WT
and NA ECL2 mutant were stimulated with thrombin, stained
with phalloidin-TRITC to visualize F-actin filaments and imaged
by confocal microscopy. Thrombin caused a marked increase in
actin stress fiber formation in PAR1 WT cells (Fig. 7A), whereas
the response was significantly diminished in NA ECL2 cells (Fig.
7A). Inhibition of RhoA activation with C3 toxin virtually abol-
ished thrombin-induced actin stress fiber formation in PAR1 WT
cells (Fig. 7B), consistent with G12/13-induced RhoA-mediated
stress fiber formation as previously reported (27). These results
suggest that N-linked glycosylation of PAR1 at ECL2 regulates
preferential coupling to G12/13 and induction of RhoA-medi-
ated stress fiber formation.
Thrombin activation of PAR1 promotes Gq-dependent mi-
togenic responses in fibroblasts (28, 29). To determine if
N-linked glycosylation of PAR1 at ECL2 affects thrombin-
induced cellular proliferation, [3H]thymidine incorporation was
measured to assess DNA synthesis in fibroblasts. In these
studies, mouse lung fibroblasts derived from Par1−/− gene
knockouts stably expressing PAR1 WT or NA ECL2 mutant
were deprived of serum and incubated with thrombin, and the
amount of [3H]thymidine incorporation was quantified. Remarkably,
fibroblasts expressing PAR1 NA ECL2 displayed a higher basal level
of [3H]thymidine incorporation compared with WT fibroblasts (Fig.
7C), despite lower cell surface expression of PAR1 NA ECL2
compared with WT receptor (Fig. S7C). Moreover, a substantially
greater increase in [3H]thymidine incorporation was observed in
thrombin-stimulated PAR1 NA ECL2 fibroblasts relative to un-
treated control or WT fibroblasts (Fig. 7D), whereas the cells
responded equivocally to serum stimulation (Fig. 7D). Together,
these findings strongly suggest that N-linked glycosylation of PAR1
at ECL2 regulates preferential coupling to G12/13 versus Gq proteins,
which modulate the robustness of thrombin-induced cellular re-
sponses in various cell types.
Discussion
In the present study, we define a novel function for N-linked
glycosylation of a GPCR in regulation of G-protein signaling
bias. A PAR1 mutant deficient in glycosylation at ECL2
favored coupling to Gq-mediated PI signaling over G12/13-induced
Fig. 4. PAR1 WT and NA ECL2 differentially associate with Gα12. (A) FLAG–
PAR1 WT or NA ECL2 HeLa cells transfected with Gα12–EE were treated with
10 nM α-Th, immunoprecipitated, and immunoblotted. Data (mean ± SD; n = 3)
are from three independent experiments and were significant (*P < 0.05;
**P < 0.01). (B) COS-7 cells cotransfected with PAR1 WT–YFP or NA ECL2–YFP
and Gα12–Rluc were treated with 10 nM α-Th, and BRET was determined.
Data shown (mean ± SD; n = 3) from three independent experiments were
significant (**P < 0.01). NS, not significant.
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RhoA activation, opposite of the glycosylated WT receptor.
Moreover, endogenous PAR1 lacking glycosylation exhibited
an enhanced G-protein-mediated PI response and reduced
RhoA activation, in contrast to native receptor. Intriguingly,
both PAR1 WT and mutant were equally effective at coupling
to Gi and β-arrestin-1. N-linked glycosylation of PAR1 at ECL2
also enhanced thrombin-induced RhoA-mediated stress fiber
formation and attenuated cellular proliferation in fibroblasts,
consistent with preferential coupling to G12/13 versus Gq proteins.
These studies are the first, to our knowledge, to show that
N-linked glycosylation of a GPCR is critical for G-protein cou-
pling specificity.
The best described function for N-linked glycosylation of
mammalian GPCRs is in proper folding of the nascent protein
during translation and export to the cell surface. The majority
∼90% of Class A GPCRs contain N-linked glycosylation N–X–
S/T consensus sequences within their N terminus, whereas only
∼30% of the receptors contain consensus sites within the ex-
tracellular loops (30). The extent of glycosylation and full uti-
lization of consensus sites likely varies with a given GPCR.
PAR1 contains five consensus sites for N-linked glycosylation,
three in the N terminus and two in ECL2, and all appear to be
modified by glycosylation (18). We previously showed that
glycosylation of PAR1 at the N terminus and not the ECL2 is
important for efficient transport to the cell surface (18). In
addition to cell surface export, other studies suggest a function
for N-linked glycosylation in GPCR dimerization. N-linked
glycosylation was shown to contribute to the stabilization of bra-
dykinin-B2 receptor homodimerization (31), whereas β1-and
α2-adrenergic receptor (AR) heterodimerization was inhibited by
glycosylation (32). Although PAR1 NA ECL2 appears largely as a
monomer based on immunoblotting analysis (Figs. 1, 4, and 5), a
minor higher molecular weight species was sometimes evident.
However, we failed to confirm a difference in PAR1WT versus NA
ECL2 mutant dimerization. Another study reported that N-linked
glycosylation of the sphingosine-1-phosphate receptor effects
caveolae localization (33). Surprisingly, PAR1 distribution into
caveolae was not affected by loss of glycosylation at ECL2 (Fig.
S1D). Thus, these findings suggest that glycosylation of PAR1 at
ECL2 likely serves a distinct function not related to surface ex-
port, dimerization, or partitioning into caveolae.
Glycosylation can also influence GPCR–ligand interactions.
PAR2, a GPCR related to PAR1, is cleaved and activated by
trypsin-like serine proteases but not by thrombin (1). N-linked
Fig. 5. PAR1 WT and NA ECL2 are equally effective at coupling to Gi and β-arrestin-1. (A) COS-7 cells coexpressing increasing PAR1 WT–YFP or NA ECL2–YFP
with a constant amount of Gαi–Rluc were analyzed by BRET. Data are representative of three independent experiments. (B) COS-7 cells coexpressing PAR1
WT–YFP or NA ECL2–YFP and Gαi–Rluc were treated with 10 nM α-Th, and BRET was determined. Data (mean ± SD; n = 3) are representative of three in-
dependent experiments. (C) COS-7 cells coexpressing PAR1 WT–YFP or NA ECL2–YFP and Gαi–Rluc were stimulated with 10 nM α-Th, immunoprecipitated, and
immunoblotted. Data (mean ± SD; n = 3) are from three independent experiments and were significant (***P < 0.001). (D) COS-7 cells coexpressing PAR1 WT–
YFP or NA ECL2–YFP and β-arrestin-1–Rluc were stimulated with 10 nM α-Th, and BRET was determined. The data (mean ± SD; n = 3) are representative of
three independent experiments. (E) PAR1 surface expression (mean ± SD; n = 3) was measured by ELISA.















glycosylation of PAR2 at the N terminus was shown to affect
tryptase but not trypsin cleavage (34), indicating that glycosyl-
ation directly affects protease recognition and receptor acti-
vation. We previously showed that N-linked glycosylation of PAR1
at either the N terminus or ECL2 has no effect on the rate of re-
ceptor cleavage by thrombin (18). Intriguingly, differential glyco-
sylation of the gonadotrophin follicle-stimulating hormone (FSH)
ligand modulates the capacity of the cognate FSH receptor to
couple to Gs versus Gi signaling (35). These findings indicate that
naturally occurring heterogeneity of glycosylation of certain peptide
hormones can affect GPCR-biased signaling. However, whether
naturally occurring glycosylation of GPCRs affects G-protein sig-
naling bias has not been previously reported.
Significant efforts have been made toward understanding the
mechanisms by which certain GPCRs couple to multiple dis-
tinct G-protein subtypes in the same cell, but it remains poorly
understood. Our results suggest that N-linked glycosylation of
PAR1 at ECL2 regulates G-protein coupling specificity. The
ECL2 of other class A GPCRs has also been shown to control
ligand-directed effects (36, 37). Thus, we hypothesize that
N-linked glycosylation of PAR1 at ECL2 provides structural
diversity that influences ligand–receptor interaction that favors
coupling to G12/13 versus Gq proteins. The observed PAR1 WT
and NA ECL2 mutant bias signaling is not due to alterations in
expression of PAR1, G proteins, or intracellular effectors, be-
cause differential signaling was seen in the same cell types. In
addition, the ΔΔLog(τ/KA) index is a normalized number that
takes into account differences in expression (26). Specifically,
the effects were expressed in terms of a reference pathway,
namely, activation of Gi protein where the mutation caused
minimal effect (26). Thus, our studies support a role for
N-linked glycosylation in stabilization of a distinct active PAR1
state that selectively couples to G12/13 over Gq protein, but has
no influence on receptor coupling to Gi or β-arrestin-1. Prior
studies showed a role for phosphorylation in isoproterenol-
stimulated β2–AR switching from Gs to Gi (38). In this case,
β2–AR initial coupling to Gs is required for protein kinase
A-mediated phosphorylation of ICL3 that promotes coupling
to Gi. In contrast to the β2–AR, we show that the existing status
of PAR1 N-linked glycosylation before ligand stimulation is
critical for specifying coupling to distinct G-protein subtypes.
Our studies suggest that PAR1 is likely to exist as an ensemble
of active states that use different molecular determinants to cou-
ple to distinct G-protein subtypes that are stabilized in part by
N-linked glycosylation at ECL2. Surprisingly, a role for glycosyl-
ation in modulating GPCR allostery and signaling has not been
previously explored. The heterogeneity of glycosylation indicates
that GPCRs are likely to exist as populations of receptors con-
taining distinct glycan structures even when expressed in the same
cell (39). The contribution of these diverse structures to GPCR
Table 1. PAR1 WT and NA ECL2 mutant bias coefficients
PAR1 WT PAR1 NA ECL2
Pathway log(τ/KA) Δlog(τ/KA) log(τ/KA) Δlog(τ/KA) ΔΔlog(τ/KA) Bias, ±95% c.i.
Gi (ref.) 8.35 ± 0.23 8.14 ± 0.23
RhoA 9.54 ± 0.23 1.19 ± 0.3 9.09 ± 0.23 0.95 ± 0.3 −0.24 ± 0.42 0.58, 0.22–1.54
PI hydrolysis 8.53 ± 0.20 0.18 ± 0.3 9.04 ± 0.20 0.90 ± 0.3 0.72 ± 0.42 5.27, 1.98–13.98
The operational model of agonism was used to quantify PAR1 WT versus NA ECL2 mutant bias toward G12/13-
induced RhoA activation and Gq-stimulated PI hydrolysis. The Gi pathway exhibits the least bias and was desig-
nated as the reference pathway (ref.). The ΔΔlog(τ/KA) value is a measure of the calculated bias for each
pathway, with errors corresponding to 95% confidence interval (c.i.).
Fig. 6. Glycosylation-deficient endogenous PAR1 exhibits enhanced PI hydrolysis and diminished RhoA activation. (A) Endothelial cells incubated with
0.25 μg/mL tunicamycin (TNC) for 18 h and treated with 10 nM α-Th. Cells were lysed, immunoprecipitated, and immunoblotted. Asterisk (*) is a nonspecific band.
(B) TNC-treated and untreated endothelial cells labeled withmyo-[3H]inositol were stimulated with 10 nM α-Th, and [3H]IPs were measured. Data (mean ± SD;
n = 3) were normalized to PAR1 surface expression from three independent experiments and were significant (**P < 0.01). (C) Endothelial cells treated with
or without TNC and 10 nM α-Th were processed for GST-RBD pull-down assays, and RhoA activation was determined. Data (mean ± SD, n = 4) were nor-
malized to PAR1 surface expression and were significant (*P < 0.05).
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function is not known. PAR1 is extensively glycosylated but the
nature and diversity of N-glycan modification have not been de-
termined. Importantly, naturally occurring mutations in N-linked
glycosylation consensus sequences of Rhodopsin have been linked
to retinitis pigmentosa (40, 41), indicating that modulation of
GPCR glycosylation status can contribute to disease progression.
However, mutations in PAR1 N-linked glycosylation sites have not
been identified. In summary, our findings demonstrate for the first
time, to our knowledge, that N-linked glycosylation of a GPCR
specifies coupling to distinct G-protein subtypes in the same cell.
Materials and Methods
Reagents and Antibodies. Human α-thrombin (α-Th) was from Enzyme Research
Laboratories. SFLLRN was synthesized at Tufts University Core Facility. Insulin,
transferrin, selenous acid (ITS) premix, caveolin-1, and anti-early endo-
somal antigen-1 (EEA1) antibodies were from BD Biosciences. ERK1/2 an-
tibodies were from Cell Signaling Technologies. C3 transferase toxin was
from Cytoskeleton, Inc. Polyclonal and M2 monoclonal anti-FLAG anti-
body, TRITC-conjugated phalloidin, tunicamycin, EGF, and anti-β-actin anti-
body were from Sigma. The anti-PAR1 WEDE antibody was from Beckman
Coulter. Anti-PAR1 polyclonal antibody was generated against the YEPFWE-
DEEKNESGLTEYC peptide. RhoA, Gαq/11, Gα12, and Gα13 antibodies were from
Santa Cruz Biotechnology. Renilla Luciferase antibody was from Millipore.
Horseradish peroxidase (HRP)-conjugated goat anti-mouse and anti-rabbit
antibodies were from Bio-Rad Laboratories.
cDNAs and Cell Lines. HeLa cells stably expressing N-terminal FLAG-tagged
PAR1WT and NA ECL2 were generated as described in ref. 18. HA–Gαq plasmid
was from Philip Wedegaertner, Thomas Jefferson University, Philadelphia, PA.
Gα12–EE and Gα13–EE constructs were from Dr. John Hepler, Emory University,
Atlanta, GA. Gαi–Rluc, Gα12–Rluc, Gα13–Rluc, and PAR1–YFP plasmids were from
Dr. Jean-Philippe Pin, Montpellier University, Montpellier, France. PAR1–YFP NA
ECL2 mutant was generated by site-directed mutagenesis using the QuikChange
Mutagenesis kit (Stratagene) and confirmed by dideoxy sequencing. COS-7, HeLa,
and endothelial cells were cultured as described in refs. 18, 21, and 42.
Fig. 7. PAR1 NA ECL2 exhibits diminished stress fiber formation and enhanced cellular proliferation. (A) FLAG–PAR1 WT or FLAG–NA ECL2 mutant HeLa
cells were treated with 10 nM α-Th for 5 min, stained with phalloidin-TRITC, and imaged. Data (mean ± SD; n = 3) for f-actin fluorescence were quantified
from four different images of three independent experiments and were significant (*P < 0.05). (Scale bar, 10 μm.) (B) FLAG–PAR1 WT HeLa cells pre-
treated with 1.5 μg/mL C3 toxin for 4 h at 37 °C or DMSO were incubated with 10 nM α-Th for 5 min and stained with phalloidin-TRITC, and f-actin
fluorescence was quantified. Data (mean ± SD; n = 3) were significant (***P < 0.001). (Scale bar, 10 μm.) (C) Mouse lung fibroblasts expressing FLAG–PAR1
WT or NA ECL2 mutant were incubated without (basal) or (D) with 10 nM α-Th or 2% FBS, and [3H]thymidine incorporation was measured. Basal
[3H]thymidine incorporation (mean ± SD; n = 3) is from three independent experiments and was significant (***P < 0.001). Data (mean ± SD; n = 3) are from
α-Th-stimulated [3H]thymidine incorporation from three independent experiments and were significant (*P < 0.05). NS, not significant.















Cell Transfections. See SI Materials and Methods.
PAR1 Immunoprecipitation and Immunoblotting. Equivalent amounts of lysates
from cells grown in six-well plates were processed for PAR1 immunoprecipitation
as described in ref. 18.
PAR1 Cell Surface ELISA. HeLa and COS-7 cells expressing FLAG–PAR1 WT or NA
ECL2 mutant were grown in 24-well plates and processed for cell surface ELISA
as described in ref. 18.
PI Hydrolysis. Cells were labeled overnight with 1 μCi/mL of myo-[3H]inositol
(American Radiolabeled Chemicals) and treated with agonists, and accu-
mulated [3H]IPs were measured as described in ref. 18.
BRET Assays. COS-7 cells transiently expressing PAR1WT–YFP or NA ECL2–YFP
and either G protein–Rluc or β-arrestin-1–Rluc were treated with agonists
and analyzed by BRET as described in ref. 42.
RhoA Activity Assay. Equivalent amounts of lysateswere used for GST-RBD pull-
down assays as described in ref. 19.
Calculation of Bias Coefficients. See SI Materials and Methods.
Phalloidin Staining. See SI Materials and Methods.
[3H]Thymidine Incorporation. See SI Materials and Methods.
Data Analysis. Data were analyzed by GraphPad Prism 4.0 software. Sta-
tistical analysis was determined by performing Student’s t test, one-way
ANOVA and Dunnett’s multiple test, or two-way ANOVA and Bonferroni
posttest. Data fitting to the operational model of agonism was performed
using MATLAB.
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